Maxonis

Maxonis is developing a peptide-hydrogel therapeutic that promotes nerve tissue regeneration following spinal cord injury (SCI) and peripheral nerve injury (PNI). Current treatment options for nerve repair are limited, invasive, and often yield poor functional recovery, leaving patients with few effective solutions. Ma

Maxonis is a company in neuro.

Profile

Maxonis is developing a peptide-hydrogel therapeutic that promotes nerve tissue regeneration following spinal cord injury (SCI) and peripheral nerve injury (PNI). Current treatment options for nerve repair are limited, invasive, and often yield poor functional recovery, leaving patients with few effective solutions. Maxonis’ off-the-shelf injectable hydrogel delivers the patented laminin-derived peptide LDP-196 to stimulate localized […]

The company sits in the neuro segment, where it competes on its core product or service.

The company is listed at the Creative Destruction Lab alumni company stage of development.

Website: www.maxonis.com